Andrew Johns, MD

Clinical Fellow, Hematology and Medical Oncology
MD Anderson Cancer Center

I am a third-year clinical fellow and the Chief Fellow for education in the hematology and medical oncology program at University of Texas MD Anderson Cancer Center in Houston. I will be joining on faculty with the Department of Genitourinary Medical Oncology at MD Anderson starting in July 2024. My research interests are in novel therapeutics for kidney cancer and rare GU malignancies including penile and testicular cancer, advanced imaging analytics, and clinical trial development.

Poster(s):

• 52: CABOSUN II: A Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib (CABO) vs. Sunitinib (SUN) for Non-Clear Cell Renal Cell Carcinoma (NCCRCC)

• 53: Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with tivozanib (TIVO) in the contemporary treatment landscape: The MD Anderson Cancer Center (MDACC) experience